Compare AstraZeneca plc (AZN) vs Fastly Inc (FSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Fastly Inc — how do they compare? AstraZeneca plc trades at $169.31 (market cap $253.13B), while Fastly Inc trades at $19.52 (market cap $3.27B). The key difference: AstraZeneca plc is far larger — about 77.4× Fastly Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Fastly Inc pays none. Which is the better fit depends on your goals.
| AZN | FSLY | |
|---|---|---|
Market Cap | $253.13B | $3.27B |
Sector | Health | Technology |
52-Week High | $209.48 | $33.50 |
52-Week Low | $137.44 | $6.36 |
Enterprise Value | $279.37B | $3.34B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Fastly (FSLY) trades at $20.03, up 2.25% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.13 versus $0.08, and revenue growth accelerating to 20% year-over-year. Recent news highlights strategic partnerships for digital sustainability and edge AI commerce, while cash flow trends indicate potential stabilization with 2026 net cash flow projected positive at $21 million.
Outlook remains cautiously optimistic with a consensus price target of $24.25 offering 21% upside, though persistent net losses and negative ROE pose risks. Investor sentiment is mixed with 29% buy ratings amid competitive pressures in edge cloud services. Key catalysts include Q2 2026 earnings on August 5 and execution on margin expansion targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
